Title:
CD47 ANTIBODIES AND USES THEREOF FOR TREATING CANCER
Document Type and Number:
WIPO Patent Application WO/2019/108733
Kind Code:
A3
Abstract:
Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
Inventors:
GARDAI SHYRA (US)
LEVENGOOD MATTHEW (US)
TRANG VIVIAN (US)
WESTENDORF LORI (US)
CAROSINO CHRISTOPHER (US)
FELDHAUS MICHAEL (US)
LAW CHE-LEUNG (US)
LEVENGOOD MATTHEW (US)
TRANG VIVIAN (US)
WESTENDORF LORI (US)
CAROSINO CHRISTOPHER (US)
FELDHAUS MICHAEL (US)
LAW CHE-LEUNG (US)
Application Number:
PCT/US2018/062961
Publication Date:
August 15, 2019
Filing Date:
November 29, 2018
Export Citation:
Assignee:
SEATTLE GENETICS INC (US)
International Classes:
A61P35/00; C07K16/28
Domestic Patent References:
| WO2017121771A1 | 2017-07-20 | |||
| WO2011143624A2 | 2011-11-17 | |||
| WO2016179335A1 | 2016-11-10 | |||
| WO2015048329A2 | 2015-04-02 |
Foreign References:
| US20160152711A1 | 2016-06-02 |
Other References:
I-JU CHEN ET AL: "Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains", SCIENTIFIC REPORTS, vol. 7, no. 1, 14 September 2017 (2017-09-14), XP055586093, DOI: 10.1038/s41598-017-11886-7
Attorney, Agent or Firm:
SCARR, PHD, Rebecca B. et al. (US)
Download PDF: